US4866050A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ultrasonic transdermal application of steroid compositions
Assignee: Individual
•
Filing: 1988-04-27
•
Granted: 1989-09-12
•
Expires: 2008-04-27
Abstract
Abstract A dexamethasone delivery composition includes dexamethasone disposed in a cellulosic gel, preferably a hydroxycellulose gel. Lidocaine solubilizes the dexamethasone into the gel to provide a dexamethasone composition of increased concentration and enhanced tissue penetration capability. A method for the transdermal delivery of dexamethasone includes the step of applying the dexamethasone gel composition of the invention to the tissue of a patient and applying ultrasound at the site to effect penetration of the dexamethasone.
Inventors
- 👤 Daniel Ben-Amoz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:14
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/06; A61K47/16; A61K47/18; A61K31/00; A61K31/56; A61K31/57; A61K47/30; A61K47/36; A61K47/38; A61K9/00; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
74 words
A method for the transdermal application of a steroid, comprising the steps of applying to a site on a patient where penetration is desired, a composition comprising a cellulosic gel, a steroid disposed in said gel, and at least one solubilizing agent selected from the group consisting of lidocaine, bupivacaine, etidocaine, pyrrocaine and applying ultrasonic energy to said site, whereby said steroid in said gel is driven through the tissue membrane of said patient.
Claim 2
Independent Claim
74 words
A method for the transdermal application of a steroid, comprising the steps of applying to a site on a patient where penetration is desired, a composition comprising a cellulosic gel, a steroid disposed in said gel, and at least one solubilizing agent selected from the group consisting of lidocaine, bupivacaine, etidocaine, pyrrocaine and applying ultrasonic energy to said site, whereby said steroid in said gel is driven through the tissue membrane of said patient.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein the steroid is a glucocorticoid.
Claim 4
Dependent Claim
14 words
The method of claim 2, wherein the steroid is dexamethasone or a derivative thereof.
Claim 5
Dependent Claim
11 words
The method of claim 3, wherein the gel is a carboxymethylcellulose.
Claim 6
Dependent Claim
14 words
The method of claim 4, wherein the composition further comprises distilled water and glycerin.
Claim 7
Dependent Claim
23 words
The method of claim 1, wherein said composition comprises about 0.4% dexamethasone, about 0.1% lidocaine, about 1.2% glycerin, the balance being carboxymethylcellulose gel.
Claim 8
Dependent Claim
21 words
The method claim 1 wherein said steroid is selected from the group consisting of dexamethasone, betamethasone, prednisolone and the derivatives thereof.
References Cited (Backward Citations)
US3007923A
Cited
US3962430A
Cited
US4440777A
Cited
US4701451A
Cited
US4482539A
Cited
US4710497A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-11 | 1993-03-13 | 1993-09-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-11 | 1997-03-13 | 1997-09-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-11 | 2001-03-13 | 2001-09-12 | $7700.00 | Window Closed / Lapsed |